Key result
Obesity and type 2 diabetes were associated with decreased circulating betatrophin levels compared to lean normoglycemic individuals.
Cross-Sectional (n=153)
Serum betatrophin is decreased in human obesity and further reduced in obesity-associated insulin resistance, suggesting it may serve as a potential biomarker for cardiometabolic risk.
Answers are grounded in this paper and cite their sources.
No immediate clinical implications for betatrophin measurement; leaves open its utility as a cardiometabolic biomarker pending prospective validation.
CONTEXT: Betatrophin is a secreted protein recently involved in β-cell replication with a potential role in type 2 diabetes mellitus (T2D). OBJECTIVE: The aim of the present study was to compare the circulating concentrations of betatrophin in human obesity and T2D. DESIGN, SETTING, AND PARTICIPANTS: Serum concentrations of betatrophin were measured by ELISA in 153 subjects: 75 obese normoglycemic subjects (OB-NG), 30 obese subjects with impaired glucose tolerance (OB-IGT), and 15 obese subjects with T2D (OB-T2D) matched by sex, age, and body adiposity, in comparison with 33 lean normoglycemic individuals (LN-NG). RESULTS: Circulating levels of betatrophin were significantly decreased in obese individuals and further diminished in IGT and T2D participants (LN-NG, 45.1 ± 24.4 ng/mL; OB-NG, 26.9 ± 15.4 ng/mL; OB-IGT, 18.3 ± 10.7 ng/mL; OB-T2D, 13.5 ± 8.8 ng/mL; P < .001). A marked sexual dimorphism was found, with betatrophin levels being significantly higher in women than in men (males, 21.1 ± 16.0 ng/mL; females, 34.1 ± 20.1 ng/mL; P < .001). Interestingly, betatrophin levels were positively correlated with the quantitative insulin sensitivity check index (r = 0.46; P < .001) and with high-density lipoprotein-cholesterol concentrations (r = 0.51; P < .001). CONCLUSIONS: We conclude that serum betatrophin is decreased in human obesity, being further reduced in obesity-associated insulin resistance. Betatrophin levels are closely related to obesity-associated cardiometabolic risk factors, emerging as a potential biomarker of insulin resistance and T2D.
No takes yet. Share an insight, caveat, or question.
Gómez‐Ambrosi et al. (2014) conducted a cross-sectional in Obesity and Type 2 Diabetes (n=153). Obesity and Type 2 Diabetes vs. Lean normoglycemic individuals was evaluated on Circulating concentrations of betatrophin (p=<.001). Obesity and type 2 diabetes were associated with decreased circulating betatrophin levels compared to lean normoglycemic individuals.
Synapse has enriched 10 related papers. Consider them for comparative context: